Lennox-Gastaut Syndrome - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 68 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lennox-Gastaut Syndrome - Pipeline Review, H2 2016, provides an overview of the Lennox-Gastaut Syndrome (Central Nervous System) pipeline landscape.

Lennox-Gastaut syndrome is a severe form of epilepsy that typically becomes apparent during infancy or early childhood. The most common types of seizures associated with Lennox-Gastaut syndrome are tonic and atonic seizures. Causes of Lennox-Gastaut syndrome include cortical dysplasia, congenital infections, stroke, trauma, perinatal hypoxia, infections of the central nervous system such as encephalitis or meningitis and a rare, genetic disorder called tuberous sclerosis. Treatment includes antiepileptic drugs, dietary therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Lennox-Gastaut Syndrome - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Lennox-Gastaut Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lennox-Gastaut Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Lennox-Gastaut Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Lennox-Gastaut Syndrome.

Lennox-Gastaut Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Lennox-Gastaut Syndrome (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Lennox-Gastaut Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Lennox-Gastaut Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Lennox-Gastaut Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Lennox-Gastaut Syndrome (Central Nervous System)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Lennox-Gastaut Syndrome (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Lennox-Gastaut Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Lennox-Gastaut Syndrome Overview 6
Therapeutics Development 7
Pipeline Products for Lennox-Gastaut Syndrome - Overview 7
Pipeline Products for Lennox-Gastaut Syndrome - Comparative Analysis 8
Lennox-Gastaut Syndrome - Therapeutics under Development by Companies 9
Lennox-Gastaut Syndrome - Therapeutics under Investigation by Universities/Institutes 10
Lennox-Gastaut Syndrome - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Lennox-Gastaut Syndrome - Products under Development by Companies 14
Lennox-Gastaut Syndrome - Products under Investigation by Universities/Institutes 15
Lennox-Gastaut Syndrome - Companies Involved in Therapeutics Development 16
Eisai Co Ltd 16
GW Pharmaceuticals Plc 17
INSYS Therapeutics Inc 18
Zogenix Inc 19
Lennox-Gastaut Syndrome - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 26
Drug Profiles 28
cannabidiol - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
cannabidiol - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
fenfluramine hydrochloride - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
NRP-2945 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
perampanel - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Small Molecules to Inhibit Voltage Gated Sodium Channels for Lennox Gastaut Syndrome - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Lennox-Gastaut Syndrome - Product Development Milestones 51
Featured News & Press Releases 51
Nov 22, 2016: New Data on Zogenixs ZX008 for Lennox Gastaut Syndrome & Dravet Syndrome to be Presented at 70th Annual American Epilepsy Society Meeting 51
Oct 28, 2016: Eisai To Initiate Two Phase III Clinical Studies For Antiepileptic Drug Perampanel (Fycompa) in Pediatric Patients With Partial-Onset or Primary Generalized Tonic-Clonic Seizures And In Patients With Seizures Associated With Lennox-Gastaut Syndrome 52
Sep 26, 2016: GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome 54
Jun 27, 2016: GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome 56
Feb 25, 2016: Edison Issues ADR Update on GW Pharmaceuticals 58
Dec 07, 2015: GW Pharmaceuticals Announces New Physician Reports of Epidiolex Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy 58
Jun 11, 2015: GW Pharmaceuticals Initiates Second Phase 3 Pivotal Study of Epidiolex in Lennox-Gastaut Syndrome 61
May 11, 2015: GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex (CBD) in Lennox-Gastaut Syndrome 62
Apr 23, 2015: Insys Therapeutics Commences Dosing in Phase 1/2 Safety and Pharmacokinetic Study of Cannabidiol Oral Solution in Pediatric Epilepsy Patients 63
Jan 12, 2015: Insys Therapeutics To Initiate Phase III study For An Epileptic Drug 63
Jun 25, 2014: Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Rare Form of Epilepsy, Lennox-Gastaut Syndrome 64
May 07, 2014: GW Pharmaceuticals Receives Investigational New Drug From FDA for Phase 2/3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome 64
Feb 28, 2014: GW Pharmaceuticals Receives Orphan Drug Designation by FDA for Epidiolex in the Treatment of Lennox-Gastaut Syndrome 65
Sep 25, 2006: FDA Approves New Epilepsy Indication For Lamictal 66
Jan 15, 2004: New Expanded Indication For Lamictal Offers Additional Treatment Options For Adults With Partial Seizures 66
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 67
Disclaimer 68

List of Tables

Number of Products under Development for Lennox-Gastaut Syndrome, H2 2016 7
Number of Products under Development for Lennox-Gastaut Syndrome - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Lennox-Gastaut Syndrome - Pipeline by Eisai Co Ltd, H2 2016 16
Lennox-Gastaut Syndrome - Pipeline by GW Pharmaceuticals Plc, H2 2016 17
Lennox-Gastaut Syndrome - Pipeline by INSYS Therapeutics Inc, H2 2016 18
Lennox-Gastaut Syndrome - Pipeline by Zogenix Inc, H2 2016 19
Assessment by Monotherapy Products, H2 2016 20
Number of Products by Stage and Target, H2 2016 22
Number of Products by Stage and Mechanism of Action, H2 2016 24
Number of Products by Stage and Route of Administration, H2 2016 25
Number of Products by Stage and Molecule Type, H2 2016 27